Status: Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
Participants needed: 208
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: IDEAYA BiosciencesUpdated: Jan 23, 2026Locations: 39
Eligibility criteria
Are willing to participate in this clinical study, understand the study procedur... [+7]
Have mixed SCLC and nonsmall cell lung cancer histology (SCLC with components of... [+27]